Ge Long Hui A P P·2026-01-20 08:11Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of its self-developed B023 cell injection [1] Group 1: Product Development - B023 cell injection is an innovative Class I biopharmaceutical developed and produced by Shanghai Pharmaceuticals Biotherapy, targeting locally advanced or metastatic solid tumors that are inoperable and have no effective treatment options after standard therapy failure [1] - The core component of B023 is invariant natural killer T (iNKT) cells, which are a type of non-classical T cell with a constant T cell receptor (TCR) [1] - Human iNKT cells have TCR chains TCRvα24 and TCRvβ11, which recognize lipid antigens presented by MHC class I molecule CD1d [1] Group 2: Clinical Implications - CD1d is non-polymorphic in the population, allowing for the allogeneic application of iNKT cells without causing graft-versus-host disease (GvHD), making it a universal cell type [1]